ホーム › 卵巣がん › テキサス › Fort Worth
Fort Worth、TXにおける卵巣がんの臨床試験
Fort Worthとその周辺地域（約30マイル以内）の拠点で、卵巣がんに関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
被験者募集中第2/3相
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
被験者募集中第1相
- START Center for Cancer Research - Texas, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- START Center for Clinical Research, Fort Worth
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
被験者募集中第2相
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8005), Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
被験者募集中第2相
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
被験者募集中第3相
- Jps Health Network, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Start Dfw, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Start - Dfw, Fort Worth
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8001), Fort Worth
Study of NTB-928 in R/R OC
被験者募集中第1相
- Start Ccbd, Llc, Fort Worth
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
被験者募集中第1相
- Xencor Investigative Site, Fort Worth
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
被験者募集中第3相
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- USOR Texas Oncology, Fort Worth
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
被験者募集中第2/3相
- Texas Oncology Paris, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
被験者募集中第1相
- START Dallas, Fort Worth
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
被験者募集中第2相
- SCRI - Texas Oncology, Fort Worth
他の都市における卵巣がんの試験
- Houston, TX89件の研究
- New York City, NY69件の研究
- Boston, MA61件の研究
- Los Angeles, CA50件の研究
- Nashville, TN49件の研究
- Arlington, VA46件の研究
- Philadelphia, PA44件の研究
- Columbus, OH39件の研究
- St. Louis, MO38件の研究
- Chicago, IL36件の研究
- San Antonio, TX31件の研究
- Cleveland, OH30件の研究
Fort Worthにおける他の研究
- 非小細胞肺癌18件の研究
- 子宮内膜がん12件の研究
- 乳がん12件の研究
- がん（全種類）9件の研究
- 前立腺がん9件の研究
- トリプルネガティブ乳がん7件の研究
- 黄斑変性症7件の研究
- 潰瘍性大腸炎7件の研究
- 腎臓がん（腎細胞がん）7件の研究
- 心不全7件の研究
- 転移性癌7件の研究
- 大腸癌7件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。